Joseph Stringfellow
Overview
Explore the profile of Joseph Stringfellow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhardwaj R, Ivans A, Stringfellow J, Morris B, Coric V, Croop R, et al.
Clin Pharmacol Drug Dev
. 2023 Apr;
12(8):790-800.
PMID: 37073443
Rimegepant is a small-molecule calcitonin gene-related peptide receptor antagonist (gepant) with demonstrated efficacy and safety in the acute and preventive treatment of migraine. Here, we report the pharmacokinetics and safety...
2.
Bhardwaj R, Collins J, Stringfellow J, Madonia J, Anderson M, Finley J, et al.
Clin Pharmacol Drug Dev
. 2022 Mar;
11(7):889-897.
PMID: 35304977
Rimegepant (Nurtec ODT)-an orally administered, small-molecule calcitonin gene-related peptide receptor antagonist indicated for the acute and preventive treatment of migraine-is a substrate for both the P-glycoprotein and breast cancer resistance...
3.
Baker T, Croop R, Kamen L, Price P, Stock D, Ivans A, et al.
Breastfeed Med
. 2022 Jan;
17(3):277-282.
PMID: 35049333
Investigate whether rimegepant-an oral small molecule calcitonin gene-related peptide receptor antagonist for the treatment of migraine-is excreted in human milk after a single 75 mg dose and characterize its concentration-time...
4.
Potkin S, Saha A, Kujawa M, Carson W, Ali M, Stock E, et al.
Arch Gen Psychiatry
. 2003 Jul;
60(7):681-90.
PMID: 12860772
Background: Aripiprazole is a dopamine D2 receptor partial agonist with partial agonist activity at serotonin 5HT1A receptors and antagonist activity at 5HT2A receptors. This multicenter trial examined the efficacy, safety,...